Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH

NCT01855854 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Adenocarcinoma of the Gastroesophageal Junction
Esophageal Carcinoma

Interventions

DRUG: Icotinib

Sponsor

Betta Pharmaceuticals Co., Ltd.